Our Scientific Contributions

We share over 300 scientific papers in dementia research.

Our scientific output helps shape international research, clinical practice, and future therapeutic development.

MARC has made significant contributions to dementia research, with more than 300 scientific papers published in leading journals across neurology, psychiatry and neuroscience. Our work spans landmark discoveries in immunotherapy, inflammation, diagnostics, neuroimaging and therapeutic development. These publications reflect decades of collaboration between clinicians, researchers and academic partners, helping to advance global understanding of dementia and shape the treatments and research methods used today.

Selected Research Publications

Liraglutide in mild to moderate Alzheimer’s disease: a phase 2b clinical trial. Paul Edison, Brady McFarlane, Clive Ballard et al. Nature Medicine 2026 https://www.nature.com/articles/s41591-025-04106-7

Inflammation in dementia with Lewy bodies. Jay Amin et al. Neurobiology of disease 2022 https://www.sciencedirect.com/science/article/pii/S0969996122000900

Psychological stress, cognitive decline and the development of dementia in amnestic mild cognitive impairment. Rebecca Sussams, Jay Amin, Clive Holmes et al. Scientific Reports 2020 https://www.nature.com/articles/s41598-020-60607-0

Neuroinflammation in Alzheimer's disease. Michael Heneka, Clive Holmes, Markus Kummer et al. The Lancet Neurology 2015 https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(15)70016-5/abstract

Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease. Robert Howard, Clive Holmes, Patrick Phillips et al. The New England Journal of Medicine 2012 https://www.nejm.org/doi/full/10.1056/NEJMoa1106668

Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Sube Banerjee, Clive Holmes, Alistair Burns et al. The Lancet 2011 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)60830-1/abstract

Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Clive Holmes, David Wilkinson, James Nicoll et al. The Lancet 2008 https://pubmed.ncbi.nlm.nih.gov/18640458/

Dr. Jay Amin
Associate Professor in Psychiatry of Older Age and Honorary Consultant in Older People's Mental Health

“At MARC our internationally recognised studies range from landmark clinical trials in The Lancet, NEJM and Nature Medicine to pioneering research in neuroinflammation, stress, and innovative treatments. They are transforming how we understand, diagnose, and treat dementia. By combining scientific excellence with compassionate clinical care, we are driving real progress and bringing hope to people and families affected by dementia today and in the future”